https://en.bioecon.ru/companies/takeda/Recent content in Takeda on BioeconHugoen-USSat, 11 Jul 2026 14:19:14 +0700https://en.bioecon.ru/technology/enzymatic-therapy-celiac/Tue, 07 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/enzymatic-therapy-celiac/Engineered enzymes and enzyme-target inhibitors are moving toward pharmaceutical protection from gluten exposure in celiac disease — a Barcelona-designed gastric enzyme validated in mouse models, a transglutaminase-2 inhibitor showing histologic protection in human trials, and a $35M Takeda-funded oral enzyme program whose later trial stage reportedly worsened mucosal damage.https://en.bioecon.ru/technology/nk-cell-car-nk-therapy/Fri, 19 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/nk-cell-car-nk-therapy/CAR-NK and NK-cell therapy — allogeneic, off-the-shelf effector cells with low toxicity (minimal CRS, no GVHD) against solid and haematological cancers; iPSC-NK is the scalable platform.